Literature DB >> 16246306

cAMP-response element-binding protein mediates prostaglandin F2alpha-induced hypertrophy of vascular smooth muscle cells.

Kae Fukuyama1, Toshihiro Ichiki, Hiroki Ono, Tomotake Tokunou, Naoko Iino, Satoko Masuda, Hideki Ohtsubo, Akira Takeshita.   

Abstract

Prostaglandin F(2alpha) (PGF(2alpha)) is a vasoactive factor that causes constriction and hypertrophy of vascular smooth muscle cells (VSMCs). However, the mechanism of PGF(2alpha)-induced hypertrophy is largely unknown. Cyclic AMP-response element (CRE)-binding protein (CREB), the best characterized stimulus-induced transcription factor, activates transcription of target genes with CRE and promotes cell growth. We examined the role of CREB in PGF(2alpha)-induced hypertrophy of VSMCs. PGF(2alpha) induced phosphorylation of CREB at serine 133, which is a critical marker of activation, after 5-10min of stimulation in a dose-dependent manner. Pharmacological inhibition of extracellular signal-regulated protein kinase and p38 mitogen-activated protein kinase (p38-MAPK) suppressed PGF(2alpha)-induced CREB phosphorylation. Inhibition of epidermal growth factor receptor (EGFR) and mitogen- and stress-activated protein kinase-1 also suppressed PGF(2alpha)-induced CREB phosphorylation. Overexpression of dominant-negative form of CREB (AdCREB M1), of which serine 133 was replaced with alanine, inhibited PGF(2alpha)-induced c-fos mRNA expression as well as hypertrophy of VSMCs [hypertrophy index (microg/10(4)cell); control 8.13, PGF(2alpha) 9.85, AdCREB M1 7.91, and AdCREB M1+PGF(2alpha) 8.43]. These results suggest that PGF(2alpha) activated CRE-dependent gene transcription through EGFR transactivation, and the CREB pathway plays a critical role in PGF(2alpha)-induced hypertrophy of VSMCs.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16246306     DOI: 10.1016/j.bbrc.2005.10.019

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  7 in total

Review 1.  Vascular effects of phytoestrogens and alternative menopausal hormone therapy in cardiovascular disease.

Authors:  V B Gencel; M M Benjamin; S N Bahou; R A Khalil
Journal:  Mini Rev Med Chem       Date:  2012-02       Impact factor: 3.862

2.  Platelet-derived growth factor BB induces nuclear export and proteasomal degradation of CREB via phosphatidylinositol 3-kinase/Akt signaling in pulmonary artery smooth muscle cells.

Authors:  Chrystelle V Garat; Dana Fankell; Paul F Erickson; Jane E-B Reusch; Natalie N Bauer; Ivan F McMurtry; Dwight J Klemm
Journal:  Mol Cell Biol       Date:  2006-07       Impact factor: 4.272

3.  Role of interferon regulatory factor 4 in the regulation of pathological cardiac hypertrophy.

Authors:  Ding-Sheng Jiang; Zhou-Yan Bian; Yan Zhang; Shu-Min Zhang; Yi Liu; Rui Zhang; Yingjie Chen; Qinglin Yang; Xiao-Dong Zhang; Guo-Chang Fan; Hongliang Li
Journal:  Hypertension       Date:  2013-04-15       Impact factor: 10.190

4.  PGF2alpha-associated vascular smooth muscle hypertrophy is ROS dependent and involves the activation of mTOR, p70S6k, and PTEN.

Authors:  K M Rice; S Uddemarri; D H Desai; R G Morrison; R Harris; G L Wright; E R Blough
Journal:  Prostaglandins Other Lipid Mediat       Date:  2007-11-17       Impact factor: 3.072

5.  CREB mediates prostaglandin F2alpha-induced MUC5AC overexpression.

Authors:  Wen-Cheng Chung; Seung-Hee Ryu; Hongxia Sun; Darryl C Zeldin; Ja Seok Koo
Journal:  J Immunol       Date:  2009-02-15       Impact factor: 5.422

6.  CREB depletion in smooth muscle cells promotes medial thickening, adventitial fibrosis and elicits pulmonary hypertension.

Authors:  Chrystelle V Garat; Susan M Majka; Timothy M Sullivan; Joseph T Crossno; Jane E B Reusch; Dwight J Klemm
Journal:  Pulm Circ       Date:  2020-04-14       Impact factor: 2.886

7.  Soluble adenylyl cyclase links Ca2+ entry to Ca2+/cAMP-response element binding protein (CREB) activation in vascular smooth muscle.

Authors:  Tony Parker; Kai-Wen Wang; Declan Manning; Caroline Dart
Journal:  Sci Rep       Date:  2019-05-13       Impact factor: 4.379

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.